What "research use only" means on a peptide label

By the PeptideLabCheck team · Last reviewed 14 November 2026 · 12 sources

Short answer

In the United States, "research use only" or "not for human consumption" on a peptide label is the seller's own statement, not an FDA approval. Under FDA's intended-use regulation (21 CFR 201.128), what counts is the seller's objective intent, which can be shown by labeling claims, advertising and the circumstances of sale ². In warning letters dated from December 2024 to August 2026, FDA said peptides carrying this wording were unapproved new drugs because the sellers' websites showed they were meant for human use ^{7, 8, 9, 10}. This guide reports what those sources say and is not legal advice.

What is a "research use only" label?

A "research use only" (RUO) or "not for human consumption" line on a vial or web page describes the purpose the seller states for the product. It is written by the seller. It is not a licence, registration or approval.

FDA regulations do contain research-only wording in two specific settings. Each comes with conditions.

Setting	Wording in the regulation	Conditions in the regulation
In vitro diagnostic products (laboratory test kits and reagents) in the laboratory research phase	"For Research Use Only. Not for use in diagnostic procedures."	The product must not be represented as an effective diagnostic product ⁴
A drug shipped solely for tests in vitro or in laboratory research animals	"CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans."	The shipper must use due diligence to assure the recipient is regularly engaged in such tests, and must keep shipment records ⁶

"In vitro" means in a test tube or dish, not in a living body.

In the sources reviewed for this guide, the exact phrase "research use only" is defined for diagnostic products. We did not find an FDA rule that defines it for peptides (see "Unverified").

Does the label change what the product legally is?

Federal law defines a drug by its intended use. Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), "drug" includes articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease. It also includes articles (other than food) intended to affect the structure or any function of the body ¹.

FDA's regulation at 21 CFR 201.128 explains how intended use is judged. It refers to the "objective intent" of the persons legally responsible for the labeling. The regulation says this intent may be shown by their expressions, by the design or composition of the article, or by the circumstances surrounding its distribution. The examples it gives include labeling claims, advertising matter, and oral or written statements ². FDA published the current text on August 2, 2021. It took effect on September 1, 2021 ³.

In the notice that issued that rule, FDA addressed disclaimers. FDA stated that limiting the evidence to promotional claims would let firms mask their true intent, for example by making claims that are not true such as "not for human use". FDA also described a 2016 federal appeals court case in which products bearing the statement "not for human consumption" were found to be subject to FDA's jurisdiction as drugs ³.

FDA has said something similar about diagnostic products. A guidance document dated November 25, 2013 states that merely placing an RUO label on such a product does not exempt it from otherwise applicable requirements, and that FDA may look at how the product is marketed ⁵. That guidance covers diagnostic devices, not peptides, and FDA guidance documents are not binding.

According to these sources, then, the label is one piece of evidence. It does not settle the question on its own.

How has FDA treated peptides labelled this way?

FDA has published warning letters to online sellers of peptides that carried research-only wording. We read four, dated December 10, 2024, February 26, 2025, March 31, 2026 and August 24, 2026 ^{7, 8, 9, 10}. Each letter says that, despite the research-only statements, evidence from the seller's website established that the products were intended to be drugs for human use. Each concludes that the named products were unapproved new drugs. In these letters, a "new drug" is one not generally recognized as safe and effective for the uses in its labeling. The letters say a new drug may not be introduced into interstate commerce (trade between states) without an approved FDA application ^{7, 9, 10}.

The evidence FDA cited in these letters included:

Product-page statements about treating disease or changing how the body works ^{7, 9}.
Summaries of laboratory or clinical studies placed on product pages ¹⁰.
Social media posts about health benefits ⁷.
Comparisons with FDA-approved brand-name medicines ⁸.
A solvent for reconstituting the products, sold on the same site ^{9, 10}.

On a public page marked current as of October 1, 2026, FDA states that it has warned companies whose unapproved products were "falsely labeled" as for research purposes or not for human consumption. FDA says these products were sold directly to consumers with dosing instructions, and describes them as of unknown quality ¹¹.

What is not settled by these sources?

A warning letter is not a court ruling. FDA describes a warning letter as a notice of what the agency believes are significant violations. The recipient can respond and can disagree. FDA says later communications and actions may change the regulatory status of the issues ¹². The letters also state that they are not a complete list of violations ^{9, 10}.

Each letter we read relied on specific website evidence. The sources reviewed do not say how FDA would view a seller that makes no claims and supplies only laboratories. This guide does not predict that.

This guide covers US federal sources only. It does not cover state law, other agencies or other countries.

What does this mean when you evaluate a vendor's website?

Read the label and the marketing together. The intended-use regulation looks at both ².

These are signs that a site's marketing conflicts with its research-only label. Each is a type of evidence FDA cited in the sources above:

Health, disease or body-function claims, including claims phrased as "research shows" ^{9, 10}.
Dosing instructions ¹¹.
Comparisons with approved brand-name medicines ⁸.
Benefit claims on the vendor's social media ⁷.
Supplies for preparing the product, sold alongside it ^{9, 10}.

A site that prints "research use only" and also does these things is contradicting its own label. That is a warning sign about how carefully the vendor handles its claims and paperwork.

Two cautions apply. The absence of these signs does not show that a product is lawful or of good quality. And a research-only label says nothing about what is in the vial. A label is not a test result.

Key facts

Under 21 U.S.C. 321(g)(1), "drug" includes articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, and articles (other than food) intended to affect the structure or any function of the body ¹.
FDA's regulation 21 CFR 201.128 says intended use means the objective intent of the persons responsible for labeling, which may be shown by labeling claims, advertising matter, or the circumstances surrounding distribution ².
FDA published the current intended-use rule in the Federal Register on August 2, 2021, with an effective date of September 1, 2021 ³.
FDA regulation 21 CFR 809.10(c)(2)(i) prescribes the statement "For Research Use Only. Not for use in diagnostic procedures." for in vitro diagnostic products in the laboratory research phase ⁴.
FDA regulation 21 CFR 312.160 requires a person shipping a drug intended solely for in vitro or laboratory animal tests to use due diligence to assure the recipient is regularly engaged in such tests ⁶.
In a warning letter dated August 24, 2026, FDA stated that despite labeling "for research use only", evidence from the seller's website established that the products were intended to be drugs for human use ¹⁰.
FDA states that it has warned companies selling unapproved products "falsely labeled" as for research purposes or not for human consumption, on a page marked current as of October 1, 2026 ¹¹.
FDA describes a warning letter as a notice of what the agency believes are significant violations, to which the recipient may respond ¹².

Common questions

Is a peptide labelled "research use only" approved by FDA?

No. The label is the seller's own statement. In the warning letters cited here, FDA said no approved applications were in effect for the products named ^{9, 10}.

Does "not for human consumption" exempt a product from US drug rules?

Not by itself, according to FDA. FDA's regulation judges intended use from the seller's statements and the circumstances of sale, and FDA has described a court case in which products with that statement were still treated as drugs ^{2, 3}.

Is it illegal to sell a peptide labelled "research use only"?

This guide cannot answer that for any product or seller. Under the regulation it depends on the intended use shown by the evidence in each case, and the FDA letters we read turned on specific website content ^{2, 10}. This is not legal advice.

Does a warning letter mean a company was found to have broken the law?

No. FDA describes a warning letter as notice of what the agency believes are significant violations. The recipient can respond and disagree, and later actions may change the status of the issues ¹².

Does a research-only label tell me anything about purity or quality?

No. The label concerns stated purpose, not contents. FDA describes the research-labelled products it warned about as being of unknown quality ¹¹.

Sources

21 U.S.C. 321 (FD&C Act section 201), "Definitions; generally", paragraph (g)(1). U.S. Government Publishing Office, United States Code, 2023 edition. https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapII-sec321.htm — Used for the statutory definition of "drug".
21 CFR 201.128, "Meaning of 'intended uses'". Electronic Code of Federal Regulations (eCFR), displayed as up to date as of November 12, 2026; source note 86 FR 41401, August 2, 2021. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-D/section-201.128 — Used for how intended use is determined.
"Regulations Regarding 'Intended Uses'", final rule, Food and Drug Administration. Federal Register, 86 FR 41383, August 2, 2021 (effective September 1, 2021). https://www.govinfo.gov/content/pkg/FR-2021-08-02/pdf/2021-15980.pdf — Used for the rule's dates and for FDA's statements about "not for human use" claims and the court case it describes (pages 41387 and 41390).
21 CFR 809.10, "Labeling for in vitro diagnostic products", paragraph (c)(2)(i). eCFR, displayed as up to date as of November 12, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809/subpart-B/section-809.10 — Used for the regulatory "For Research Use Only" statement for diagnostic products.
"Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff". FDA, November 25, 2013. https://www.fda.gov/media/87374/download — Used for FDA's statement that an RUO label alone does not exempt a diagnostic product.
21 CFR 312.160, "Drugs for investigational use in laboratory research animals or in vitro tests". eCFR, displayed as up to date as of November 12, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-G/section-312.160 — Used for the caution statement and conditions for shipping a drug for laboratory research.
Warning Letter, "Summit Research Peptides - 695607 - 12/10/2024". FDA, Center for Drug Evaluation and Research, December 10, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024 — Used for FDA's treatment of research-only wording and its citation of website and social media claims.
Warning Letter, "USApeptide.com - 696885 - 02/26/2025". FDA, Center for Drug Evaluation and Research, February 26, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025 — Used for FDA's treatment of research-only wording and its citation of brand-name comparisons.
Warning Letter, "Gram Peptides - 721806 - 03/31/2026". FDA, Center for Drug Evaluation and Research, March 31, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026 — Used for FDA's treatment of research-only wording, the "new drug" reasoning, and the evidence cited.
Warning Letter, "Peptide Partners LLC - 735063 - 08/24/2026". FDA, Center for Drug Evaluation and Research, August 24, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026 — Used for FDA's statement on "for research use only" labeling and its citation of study summaries on product pages.
"FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss". FDA, content current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss — Used for FDA's public statement on products labelled for research purposes or not for human consumption.
"About Warning and Close-Out Letters". FDA, content current as of March 20, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters — Used for what a warning letter is and how recipients can respond.